Cryptococcal Meningitis in an HCV-Positive and IVDU- and HIV-Negative Patient: A Case Report and Literature Review

• Published in: International medical case reports journal Vol. 17; pp. 855 - 860
• Main Authors: Lozada-Ramos, Heiler, Álvarez-Payares, Jorge, Daza-Arana, Jorge, Salas-Marín, Luisa
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2024; Dove; Dove Medical Press
• Subjects: Antifungal agents; Antiviral agents; B cells; Case Report; Cryptococcal meningitis; cryptococcosis; Health aspects; hepatitis c; Hepatitis C virus; HIV (Viruses); HIV infection; HIV patients; Immunotherapy; intravenous drug use; Levetiracetam; Colombia; intravenous drug use; cryptococcal meningitis; HIV infection; hepatitis C; cryptococcosis
• ISSN: 1179-142X; 1179-142X
• DOI: 10.2147/IMCRJ.S486119

Cryptococcal meningitis (CM) is a central nervous system (CNS) infection that occurs mainly in immunocompromised individuals such as those with human immunodeficiency virus (HIV) infection. However, the prevalence of CM in immunocompetent patients has increased. Although CM has been reported in patients with hepatitis C virus (HCV) infection, it has not yet been fully established whether there is an association between both conditions. CM has also been reported in patients with intravenous drug use (IVDU), which is related to the immunosuppression caused by these drugs. We report the case of a 24-year-old man who presented with meningitis secondary to infection. He had a history of IVDU and HCV infection, was HIV-negative and without antiviral treatment. The patient received adequate antifungal treatment during induction, consolidation, and maintenance phases. His condition relapsed, requiring dose adjustment, with an excellent response during clinical follow-up for both meningitis and HCV infection. A brain biopsy was requested during relapse to rule out other co-infection. The case of an individual diagnosed with cryptococcal meningitis, who had a history of IVDU and HCV infection, is presented. The coexistence of such events could shadow the prognosis of this group of subjects, related to immunosuppression that can be caused through different pathways. Having HCV and being a IVDU simultaneously could increase the risk of infection.